Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MBX

MBX Biosciences Inc

May 13 • 04:00PM ET

37.50

+0.52 1.41 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: VKTX ALT RYTM TERN MDGL

| Held by: VTI IWM IWN VXF XPH IBB SCHA VTWO USVM VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.21	Insider Own	38.06%	Shs Outstand	47.57M	Perf Week	16.75%
Market Cap	1.78B	Forward P/E	-	EPS next Y	-3.91	Insider Trans	-0.29%	Shs Float	29.48M	Perf Month	14.29%
Enterprise Value	1.35B	PEG	-	EPS next Q	-0.64	Inst Own	69.77%	Short Float	13.68%	Perf Quarter	7.14%
Income	-86.61M	P/S	-	EPS this Y	-17.75%	Inst Trans	7.20%	Short Ratio	7.15	Perf Half Y	53.12%
Sales	0.00M	P/B	4.08	EPS next Y	-39.37%	ROA	-24.79%	Short Interest	4.03M	Perf YTD	18.90%
Book/sh	9.20	P/C	4.06	EPS next 5Y	-20.53%	ROE	-25.73%	52W High	45.85 -18.21%	Perf Year	265.14%
Cash/sh	9.24	P/FCF	-	EPS past 3/5Y	-44.91% -	ROIC	-19.77%	52W Low	9.43 297.67%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.86% 8.65%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.43%	Oper. Margin	-	ATR (14)	3.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.04	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	30.79	EPS Q/Q	29.35%	SMA20	12.96%	Beta	0.86	Target Price	69.09
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	19.90%	Rel Volume	1.44	Prev Close	36.98
Employees	63	LT Debt/Eq	0.00	Earnings	May 07 BMO	SMA200	43.58%	Avg Volume	563.94K	Price	37.50
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.78% -	Trades		Volume	811,899	Change	1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$66
Dec-04-25	Initiated	Goldman	Sell	$18
Nov-04-25	Initiated	TD Cowen	Buy
Oct-15-25	Initiated	Truist	Buy	$50
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Show Previous Ratings

May-11-26 07:00AM	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing (GlobeNewswire)
May-07-26 08:00AM	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +8.06%
07:00AM	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award (GlobeNewswire)
Apr-23-26 08:00AM	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio (GlobeNewswire)
Apr-03-26 08:00AM	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Mar-12-26 08:00AM	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-26 08:00AM	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer (GlobeNewswire)
Mar-09-26 10:21AM	CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire) -8.54%
08:00AM	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire)
Feb-28-26 07:05PM	MBX Biosciences Calls 2026 Pivotal With Phase 3 Plans, Obesity Program, and $460M Cash Runway (MarketBeat)
Feb-23-26 08:00AM	MBX Biosciences to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.63%
Feb-20-26 06:53PM	TripAdvisor, Orthofix Medical, and More Stocks See Action From Activist Investors (Barrons.com) -6.63%
Feb-11-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.11%
Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11:11PM	Loading…
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
09:55AM	Loading…
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bartram Richard	Former Officer	May 13 '26	Proposed Sale	36.95	15,000	554,296		May 13 04:17 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Option Exercise	11.65	70,003	815,348	69,769	May 11 04:01 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Sale	38.36	70,003	2,685,515	14,769	May 11 04:01 PM
Bartram Richard	Former Officer	May 11 '26	Proposed Sale	44.08	22,500	991,901		May 11 03:54 PM
Azoulay Salomon	Officer	May 08 '26	Proposed Sale	38.37	70,003	2,685,679		May 08 04:10 PM
Azoulay Salomon	Chief Medical Officer	May 06 '26	Sale	29.54	231	6,824	14,769	May 08 04:02 PM
Hawryluk P. Kent	President & CEO	May 06 '26	Sale	29.54	607	17,931	727,667	May 08 04:00 PM
Bartram Richard	Former Officer	May 08 '26	Proposed Sale	37.96	10,000	379,562		May 08 12:21 PM
Bartram Richard	Former Officer	May 07 '26	Proposed Sale	32.20	10,000	322,050		May 07 12:47 PM
Hawryluk P. Kent	Officer	May 06 '26	Proposed Sale	29.54	607	17,934		May 06 03:29 PM
Azoulay Salomon	Officer	May 06 '26	Proposed Sale	29.54	231	6,825		May 06 03:12 PM
Bartram Richard	Former Officer	May 01 '26	Proposed Sale	31.80	5,000	159,000		May 01 02:59 PM
Bartram Richard	Former Officer	Apr 22 '26	Proposed Sale	32.75	10,423	341,378		Apr 22 11:59 AM
Bartram Richard	Former Officer	Mar 25 '26	Proposed Sale	28.48	1,061	30,217		Mar 25 03:20 PM
Bartram Richard	Former Officer	Mar 16 '26	Proposed Sale	30.05	10,000	300,471		Mar 16 02:47 PM
Hawryluk P. Kent	President & CEO	Mar 13 '26	Buy	28.41	18,500	525,663	486,777	Mar 16 08:02 AM
Hawryluk P. Kent	President & CEO	Feb 26 '26	Option Exercise	16.00	28,768	460,288	728,274	Feb 27 04:07 PM
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM
Hawryluk P. Kent	President & CEO	Oct 24 '25	Option Exercise	3.25	182,859	594,292	664,256	Oct 28 08:03 AM
Hawryluk P. Kent	President & CEO	Oct 20 '25	Buy	13.64	20,000	272,790	468,277	Oct 21 05:43 PM
Hoerter Steven L.	Director	Oct 17 '25	Buy	13.25	20,000	264,984	20,000	Oct 20 04:44 PM
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBX

MBX Biosciences Inc

Upgrade your Finviz experience